Abstract:Apatinib is a tyrosine kinase inhibitor which selectively inhibits VEGFR-2 and also represents mild inhibition to PDGFR, c-Kit and c-src. It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis and tumor cell proliferation. Previous clinical trials have demonstrated its obvious antitumor activity in various cancer type. Thus we designed this phase II, open-label, single-armed, prospective study (NCT02515435) to investigate the efficacy and safety of apatinib for heavily treated, advanced non-squamous NSCLC patients who are not applicable to current standardized therapy or other clinical trials. We prospectively enrolled 40 patients with previously heavily treated advanced non-squamous NSCLC. All patients received apatinib with a dose of 500mg, q.d., p.o. Efficiency was evaluated initially 4 weeks later and then every 8 weeks until disease progression, death, or unacceptable toxicity. The primary end point of this study was overall response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS). Forty patients were enrolled in the study with a median age of 61. 15% of patients received apatinib as second-line therapy, 40% of patients received apatinib as third-line therapy, and 60% as forth-line to twelfth-line therapy. Nine patients were found with activated EGFR mutation. Among all the enrolled patients, 38 patients had clinical evaluation and the other 2 received treatment of apatinib less than one month. Within 33 patients who had available image efficiency, 6 were identified as PR,17 SD and 10 PD, no CR was observed. The ORR was 18.18 %, the DCR was 69.69%. The ORR for patients with EGFR mutation positive and negative were 25% and 16% separately. The median PFS was 3.22 months (95% CI, 2.20-4.17 months). Among them, 6 patients received the treatment of apatinib more than five months. The 6-month OS rate was 76.98% (95% CI, 61.68%-92.27%), the 12-month OS rate was 57.48% (95% CI, 28.75%-86.20%). Common treatment-related adverse events were proteinuria (25%), hypertension (17.5%), and hand-foot-skin reaction (HFSR)(27.5%). Severe adverse events included grade 3 hypertension (5%), HFSR (5%), and thrombocytopenia (5%), no grade 4 or 5 adverse events were observed. No un-expected adverse events were found. Apatinib as a monotherapy had a promising overall response together with an acceptable side effect in patients with previously heavily treated advanced non-squamous NSCLC. A phase III study comparing apatinib monotherapy with placebo as 3rd/4th setting in advanced non-squamous NSCLC is ongoing to further evaluated the efficacy of apatinib (NCT02332512).

Phase 1 Dose-Escalation Study of Apatinib and Irinotecan in Esophageal Squamous Cell Carcinoma Patients

P1.12-01 A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC after Second/Third-Line Chemotherapy

A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11)

Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.

P3.02c-025 Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer

A Phase I Dose Escalation Study of Apatinib Combinated with Docetaxel As Second-line Therapy for Advanced Gastric Carcinoma

Phase I Study of Apatinib Combined with Docetaxel in EGFR-negative Advanced Non-Small Cell Lung Cancer (NSCLC).

1805P Apatinib Combined with Irinotecan in the Treatment of Small Cell Lung Cancer: A Phase II, Single-Arm, Prospective Study

Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report.

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients with Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Clinical Study on the Efficacy of Apatinib Treatment for Advanced Ovarian Cancer after Second-Line Chemotherapy Failure

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma

Apatinib Inhibits Tumor Progression and Promotes Antitumor Efficacy of Cytotoxic Drugs in Esophageal Squamous Cell Carcinoma.

A phase II study of apatinib combined with S-1 in previously treated refractory metastatic colorectal cancer.

P3.01-085 A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression

Efficacy and Safety of Apatinib with or Without Radiation Therapy As Second-Line or Beyond Therapy in Patients with Advanced/Recurrent Esophageal Squamous Cell Carcinoma

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma

A Phase I Dose-Reduction Study of Apatinib Combined with Pemetrexed and Carboplatin in Untreated EGFR and ALK Negative Stage IV Non-Squamous NSCLC

P066 A Phase I Study of Apatinib Combined with Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC

A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer

Apatinib In Patients With Adenocarcinoma Of Stomach Or Gastroesophageal Junction: A Prospective, Multicenter, Non-Interventional Study (Ahead-G202)